Related Experiment Videos
RSD-1235. Cardiome.
1Department of Physiology and Cell Biology, Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210-1218, USA. billman.1@osu.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|May 9, 2003
Summary
RSD-1235, a new mixed ion channel antagonist, is being developed to treat heart arrhythmia. Phase II trials are complete, with Phase III studies planned to begin in 2003.
Area of Science:
- Cardiovascular pharmacology
- Clinical drug development
Background:
- Novel mixed ion channel antagonist RSD-1235 is under development.
- Cardiome Pharma is leading the research for potential heart arrhythmia treatments.
Purpose of the Study:
- To evaluate the efficacy and safety of RSD-1235 for treating heart arrhythmia.
Main Methods:
- Phase II clinical trials have been completed.
- Phase III studies are scheduled to commence in 2003.
Main Results:
- Phase II trial results are pending or not detailed in the abstract.
- Data from completed Phase II trials will inform Phase III study design.
Conclusions:
- RSD-1235 shows potential as a future treatment for heart arrhythmia.
- Further clinical evaluation in Phase III trials is warranted.